Wong W - Search Results

1

A Pragmatic Guide to Assessing Real Option Value for Medical Technologies.

Li M, Garrison L Jr, Lee W, Kowal S, Wong W, Veenstra D. Li M, et al. Among authors: wong w. Value Health. 2022 Jun 22:S1098-3015(22)02002-2. doi: 10.1016/j.jval.2022.05.014. Online ahead of print. Value Health. 2022. PMID: 35752536 Free article.

2

Cost effectiveness of pharmacogenomics: a critical and systematic review.

Wong WB, Carlson JJ, Thariani R, Veenstra DL. Wong WB, et al. Pharmacoeconomics. 2010;28(11):1001-13. doi: 10.2165/11537410-000000000-00000. Pharmacoeconomics. 2010. PMID: 20936884 Review.

3

Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.

Carlson JJ, Wong WB, Veenstra DL, Reyes C. Carlson JJ, et al. J Med Econ. 2011;14(2):159-66. doi: 10.3111/13696998.2011.557457. Epub 2011 Feb 2. J Med Econ. 2011. PMID: 21288059 Free article.

4

Prioritization in comparative effectiveness research: the CANCERGEN Experience.

Thariani R, Wong W, Carlson JJ, Garrison L, Ramsey S, Deverka PA, Esmail L, Rangarao S, Hoban CJ, Baker LH, Veenstra DL; Center for Comparative Effectiveness Research in Cancer Genomics (CANCERGEN). Thariani R, et al. Among authors: wong w. Med Care. 2012 May;50(5):388-93. doi: 10.1097/MLR.0b013e3182422a3b. Med Care. 2012. PMID: 22274803 Free PMC article.

5

The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007).

Wong WB, Ramsey SD, Barlow WE, Garrison LP Jr, Veenstra DL. Wong WB, et al. Contemp Clin Trials. 2012 Nov;33(6):1117-23. doi: 10.1016/j.cct.2012.08.006. Epub 2012 Aug 18. Contemp Clin Trials. 2012. PMID: 22981891 Free PMC article. Clinical Trial.

6

Real-world evidence for option value in metastatic melanoma.

Wong WB, To TM, Li M, Lee W, Veenstra DL, Garrison LP Jr. Wong WB, et al. J Manag Care Spec Pharm. 2021 Nov;27(11):1546-1555. doi: 10.18553/jmcp.2021.21192. Epub 2021 Aug 25. J Manag Care Spec Pharm. 2021. PMID: 34431715 Free PMC article.

7

Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data.

Lee W, Li M, Wong WB, To TM, Garrison LP, Veenstra DL. Lee W, et al. Among authors: wong wb. Value Health. 2021 Dec;24(12):1746-1753. doi: 10.1016/j.jval.2021.07.004. Epub 2021 Sep 1. Value Health. 2021. PMID: 34838272 Free article.

8

Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.

Lee W, Wong WB, Kowal S, Garrison LP Jr, Veenstra DL, Li M. Lee W, et al. Among authors: wong wb. Pharmacoeconomics. 2022 Jun;40(6):623-631. doi: 10.1007/s40273-022-01147-5. Epub 2022 May 9. Pharmacoeconomics. 2022. PMID: 35527331 Free PMC article.

9

The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations.

Wong W, Kowal S, To TM, Patel A, Veenstra D, Garrison L, Li M. Wong W, et al. Future Oncol. 2024 Jan 23. doi: 10.2217/fon-2023-0514. Online ahead of print. Future Oncol. 2024. PMID: 38258557

10

Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.

Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS. Walker MS, et al. Among authors: wong w. Health Qual Life Outcomes. 2017 Aug 14;15(1):160. doi: 10.1186/s12955-017-0735-4. Health Qual Life Outcomes. 2017. PMID: 28806963 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,113 results

Search Page